Medtronic plc (MDT - Free Report) reported third-quarter fiscal 2019 adjusted earnings per share (EPS) of $1.29, beating the Zacks Consensus Estimate by 4%. Adjusted earnings rose 10.3% year over year.
Adjustments in the quarter primarily included the impact of restructuring charges, intangible asset amortization and impairment of in-process research and development (IPR&D) assets among others. After adjusting for foreign exchange tailwind of 2 cent, adjusted EPS increased 8.5% year over year.
Without the adjustments, net earnings were 94 cents per share, compared with loss of $1.03 in the year-ago quarter.
Worldwide revenues in the reported quarter grossed $7.55 billion, up 4.4% on an organic basis (up 2.4% on a reported basis). The top line missed the Zacks Consensus Estimate by 0.13%. Organic revenues in the quarter include adjustments for a $149-million negative impact from foreign currency.
In the quarter under review, U.S. sales (53% of total revenues) increased 2.3% year over year on a reported basis to $4 billion. Non-U.S. developed market revenues totaled $2.37 billion (31% of total revenues), reflecting a 0.6% increase reportedly (up 3.6% on a constant currency basis). Emerging market revenues (16% of total revenues) amounted to $1.18 billion, up 6.8% reportedly (up 13.9% on a constant currency basis).
The company currently generates revenues from four major groups, viz. Cardiac and Vascular Group (CVG), Minimally Invasive Therapies Group (MITG), Restorative Therapies Group (RTG) and Diabetes Group.
CVG comprises Cardiac Rhythm & Heart Failure (CRHF), Coronary & Structural Heart (CSH) and Aortic & Peripheral Vascular divisions (APV). MITG includes the Surgical Innovations (SI) and the Respiratory, Gastrointestinal & Renal (RGR) divisions. RTG comprises the Spine, Brain Therapies, Specialty Therapies and Pain Therapies segments, while the Diabetes Group incorporates the Intensive Insulin Management (IIM), Non-Intensive Diabetes Therapies (NDT), and Diabetes Service & Solutions (DSS) divisions.
CVG revenues improved 1.6% at constant exchange rate or CER (down 0.5% as reported) to $2.79 billion, driven by mid-single digit growth in CSH and APV offset by low-single digit drop in CRHF, all at CER.
CRHF sales totaled $1.39 billion, down 2.3% year over year at CER (down 4.1% as reported). The mid-single digits growth in Arrhythmia Managementwas offset by mid-teens declines in Heart Failure, including mid-forties declines in sales of left ventricular assist devices.
CSH revenues were up 5.9% at CER (up 3% as reported) to $913 million driven by mid-teens constant currency growth in transcatheter aortic valves as a result of strong global uptake of the CoreValve Evolut PRO platform. The company reported flat year-over-year coronary sales in the reported quarter as the mid-teens growth in guide catheters and low-double digit growth in coronary balloons were offset by mid-single digit declines in drug-eluting stents.
APV revenues registered 6.1% growth at CER (up 4.2% as reported) to $476 million, driven by mid-teens growth in Venous, mid-teens growth of in drug-coated balloon (DCB) and high-single digit growth in thoracic stent graft systems, all at comparable CER basis.
In MITG, worldwide sales totaled $2.12 billion, marking a 6.6% year-over-year increase at CER (up 4.1% on a reported basis) on high-single-digit growth in RGRand mid-single digit growth in SI.
In RTG, worldwide revenues of $2.03 billion were up 5.5% year over year at CER (up 4.2% as reported) on low-double-digit growth in Brain Therapies, mid-single-digit growth in pain therapies, low-single-digit growth in Specialty Therapies and flat performance in the Spine business.
Moreover, revenues at the Diabetes group increased 6.5% at CER (up 4.5% as reported) to $610 million.
Gross margin in the reported quarter contracted 24 basis points (bps) to 69.9% on a 3.2% rise in cost of revenues to $2.27 billion. Adjusted operating margin improved 73 bps year over year to 27.4% despite a 0.4% rise in research and development expenses (to $561 million) and a 2.9% uptick in selling, general and administrative expenses (to $2.59 billion). Other expenses in the reported quarter totaled $57 million as compared with $128 million a year ago.
The company has updated its fiscal 2019 revenue guidance.
For the full year, organic revenue growth expectations have been narrowed to the range of 5.25-5.5% from the previous range of 5.0-5.5%. Currency fluctuation is now expected to negatively impact the top line by $425-$475 million (previous guidance range was $420-$520 million). The current Zacks Consensus Estimate for revenues is pegged at $30.53 billion.
Fiscal 2019 adjusted EPS view is raised at the range of $5.14-$5.16 from the earlier-announced range of $5.10-$5.15. Currency fluctuation is expected to havea modestly positive impact on the full-year adjusted EPS. The Zacks Consensus Estimate of $5.12 falls below the guided range.
Medtronic exited third-quarter fiscal 2019 on a mixed note. While it reported a better-than-expected earnings performance, revenues missed the mark. The company has demonstrated improved performances at CER banking on growth in most of the business segments and all geographies. This highlighted sustainability across groups and regions, in addition to displaying successful integration and achievement of synergy targets. Apart from product innovation, the company is focusing on geographical diversification of its businesses.
However, we are concerned about the company’s sluggish CRHF performance. This apart, costs continue to escalate putting pressure on margins.
Zacks Rank & Peer Performances
Medtronic has a Zacks Rank #3 (Hold).
A few better-ranked medical stocks are Abbott Laboratories (ABT - Free Report) , AngioDynamics Inc. (ANGO - Free Report) and CONMED, Corp. (CNMD - Free Report) . You can seethe complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Abbott reported fourth-quarter 2018 adjusted EPS of 81 cents, in line with the Zacks Consensus Estimate. Revenues of $7.77 billion were below the Zacks Consensus Estimate of $7.79 billion. The stock has a Zacks Rank #2 (Buy).
AngioDynamics’ fiscal second-quarter adjusted EPS of 22 cents exceeded the Zacks Consensus Estimate by a penny. Revenues totaled $91.5 million, beating the consensus estimate by 2.9%. The stock sports a Zacks Rank #1.
CONMED delivered fourth-quarter adjusted EPS of 73 cents, in line with the Zacks Consensus Estimate. Revenues of $242.4 million beat the Zacks Consensus Estimate of $229.2 million. The stock carries a Zacks Rank of 2.
Is Your Investment Advisor Fumbling Your Financial Future?
See how you can more effectively safeguard your retirement with a new Special Report, “4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future.”
Click to get it free >>